A Phase II Randomized, Double-blind (Part A, B and C), Placebo Controlled (Part A and B Only), Study to Assess Safety, Tolerability and Efficacy of MCS110 on Tumor Size in Patients With Pigmented Villonodular Synovitis (PVNS)
Phase of Trial: Phase II
Latest Information Update: 11 May 2017
At a glance
- Drugs MCS 110 (Primary)
- Indications Pigmented villonodular synovitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis
- 03 May 2017 Planned number of patients changed from 37 to 39.
- 03 May 2017 Planned End Date changed from 1 Dec 2018 to 26 Sep 2019.
- 03 May 2017 Planned primary completion date changed from 1 Dec 2018 to 26 Sep 2019.